GUBRA — Gubra A/S Share News
0.000.00%
Last trade - 00:00- DKK4.95bn
- DKK4.24bn
- DKK2.64bn
Brief: Gubra Q1 EBIT Loss At DKK 43.5 Million
Brief: Monika Lessl Appointed New Chair Of Gubra Board Of Directors
Brief: Gubra Says Conditions For License Agreement On GUB014295 Satisfied
Brief: Gubra Says GUBamy Well Tolerated With Mild GI Related Adverse Events
BofA raises AbbVie's PT on deal to develop obesity drug
Gubra surges on AbbVie partnership for obesity treatment
Brief: Abbvie And Gubra Announce License Agreement
Brief: Gubra FY Adjusted EBIT Loss DKK 42 Mln
Brief: Gubra Announces Collaboration With Amylyx Pharmaceuticals
Brief: Gubra Narrows Outlook For CRO Business
Brief: Gubra Discontinues NYP2 Obesity Development with Boehringer Ingelheim
Brief: Gubra Raises Financial Outlook For 2024
Brief: Gubra Q2 Pretax Loss Narrows To DKK 20.1 Mln
Brief: Gubra Raises Outlook For 2024
Brief: Gubra Q1 Adjusted EBIT Doubles
Brief: Gubra Unveils UCN2 As Novel Anti-Obesity Drug Candidate For Healthy Weight Loss
Brief: Gubra Expects 10-15% Organic Revenue Growth In CRO In 2024
Brief: Gubra Concludes Research Agreement With UK Biotech
Brief: Gubra, Boehringer Ingelheim Sign Partnership On Obesity Treatment